$0.02
18.59% yesterday
Nasdaq, Feb 27, 08:01 pm CET
ISIN
US92765F1084
Symbol
VIRX
Sector
Industry

Viracta Therapeutics Inc Stock price

$0.02
-0.14 86.06% 1M
-0.20 89.70% 6M
-0.14 85.71% YTD
-0.74 96.97% 1Y
-2.71 99.16% 3Y
-29.38 99.92% 5Y
-466.18 100.00% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.00 14.50%
ISIN
US92765F1084
Symbol
VIRX
Sector
Industry

Key metrics

Market capitalization $910.00k
Enterprise Value $-3.31m
P/E (TTM) P/E ratio negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-46.51m
Cash position $21.13m
EPS (TTM) EPS $-1.10
Short interest 0.79%

Is Viracta Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Viracta Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Viracta Therapeutics Inc:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Viracta Therapeutics Inc:

Hold
100%

Financial data from Viracta Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.44 0.44
2% 2%
-
-0.44 -0.44
2% 2%
-
- Selling and Administrative Expenses 13 13
27% 27%
-
- Research and Development Expense 33 33
8% 8%
-
-46 -46
5% 5%
-
- Depreciation and Amortization 0.44 0.44
2% 2%
-
EBIT (Operating Income) EBIT -47 -47
5% 5%
-
Net Profit -43 -43
9% 9%
-

In millions USD.

Don't miss a Thing! We will send you all news about Viracta Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Viracta Therapeutics Inc Stock News

Neutral
GlobeNewsWire
23 days ago
SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, announced today that the Company has terminated its employees and will wind down operations. The company is also exploring potential strategic alternatives for its d...
Neutral
GlobeNewsWire
2 months ago
SAN DIEGO, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that its Board of Directors has initiated a process to explore a broad range of strategic alternatives.
Neutral
GlobeNewsWire
4 months ago
- Reprioritized resources to reduce costs and enhance focus on Nana-val's development program in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) -

Company Profile

Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.

Head office United States
CEO Craig Jalbert
Employees 40
Founded 1998
Website www.viracta.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today